

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the

Dated

June 28, 2002

TECH CENTER 1600/2900

Docket No.: EGYPSA 3.0-002

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Legrain et al.

Application No.: 10/038,010

Group Art Unit: 1642

Examiner: Not Yet Assigned

Filed: January 2, 2002

For: Protein-Protein Interactions in Adipocyte Cells

Commissioner for Patents Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 28, 2002

Respectfully submitted,

Shawn P. Foley

Registration No.: 33,071

LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorneys for Applicant

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/038,010 Application Number INFORMATION DISCLOSURE January 2, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Pierre Legrain 1642 Art Unit (use as many sheets as necessary) Examiner Name EGYPSA 3.0-002 2 Attorney Docket Number of Sheet 1

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5468614	11-21-1995	Fields et al.	
	AB	4980286	12-25-1990	Morgan et al.	
	AC	5667973	09-16-1997	Fields et al.	
	AD	5283173	02-01-1994	Fields et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (ff known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>e</sub>
	BA	WO 00/66722	11-09-2000	Hybrigenics		$oxed{oxed}$
<u> </u>	BB	WO 99/42612	08-26-1999	Institut Pasteur		$\perp$
	BC	WO 00/07038	02-10-2000	Universite de Montreal		
<b>├</b> ──	BD	WO 98/34120	08-06-1998	Universite de Montreal		Ш
	BE	WO 99/28746	06-10-1999	Institut Pasteur		$\perp$
	BF	WO 92/06180	04-16-1992	University of Connecticut	<u> </u>	Ш
	BG	WO 93/14188	07-22-1993	The Regents of the University of Michigan		
	ВН	WO 93/20221	10-14-1993	Alexander Young		
	BI	WO 96/34100	10-31-1996	Centre National de la Recherche Scientifique		

E. aminos	Date	
Examiner	Considered	
Signature		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	ČA	ROBERT SERVICE "Protein arrays step out of DNA's shadow," 289 Science (2000) 16.	$\downarrow$
	СВ	MACBEATH & SCHREIBER, "Printing proteins as microarrays for high-throughput function determination," 289 Science (2000) 1760-63.	
	СС	ZIJLSTRA et al., "Germ-line transmission of a disrupted β2-microglobulin gene produced by homologous recombination in embryonic stem cells," 342 Letters to Nature (1989) 435-38.	
	CD	WU & WU "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," 262 J. Biol. Chem. (1987) 4429-32.	
	CE	JACOBY et al., "Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes," 4 Gene Therapy (1997) 1281-83.	
	CF	STEPHEN KOCHANEK, "High-capacity adenoviral vectors for gene transfer and somatic gene therapy," 10 Human Gene Therapy (1999) 2451-59.	
	CG	MILLER et al., "Use of Retroviral Vectors for Gene Transfer and Expression," 217 Methods in Enzymology Recombinant DNA Part H (1993) 581-99.	
	СН	ROBBINS & GHIVIZZANI "Viral Vectors for Gene Therapy," 80 Pharmacology & Therapeutics (1998) 35-47.	

PTO:SB:08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

,	Substitute for form 1449B/PTO					_		
	Substitute ic	) 10111 1443 <b>0</b> /1	-10		Application Number	10/038,010	RFCEI'	VED
	INFO	RMATIC	ON D	ISCLOSURE	Filing Date	January 2, 2002		,
	STAT	FMFN	ГВҮ	<b>APPLICANT</b>	First Named Inventor	Pierre Legrain	1111 1 1	2002
	01711				Art Unit	1642	361. 1 1	
		(use as many	sheets	as necessary)	Examiner Name		TOU OFNIED	1600/2000
She	et	2	of	2	Attorney Docket Number	EGYPSA 3.0-002	IECH CEMIEN	1000/2300

	T	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal.	
aminer tials	Cite No.1	serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CI	VASAVADA et al. "A contingent replication assay for the detection of protein-protein	l
1		interactions in animal cells," 88 Proc. Natl. Acad. Sci. (1991) 10686-90.	ļ
	CJ	TAKACS et al. "Mapping of interacting domains between the nucleocapsid protein and the	
		phosphoprotein of vesicular stomatitus virus by using a two-hybrid system," 90 Proc. Natl.	
		Acad. Sci. (1993) 10375-79.	_
	CK	SZABO et al. "Surface plasmon resonance and its use in biomolecular interaction analysis	
		(BIA) 5 Current Opinion in Structural Biology (1995) 699-705.	L
	CL	PEARSON & LIPMAN "Improved tools for biological sequence comparison," 85 Proc. Natl.	1
		Acad. Sci. (1988) 2444-8.	L
	CM	NEEDLEMAN & WUNSCH, "A general method applicable to the search for similarities in the	
		amino acid sequence of two proteins," 48 J. Molecular Biology (1970) 443-53.	L
	CN	SMITH & WATERMAN "Overlapping genes and information theory" Letter to the Editor, 91 J.	
	1	Theoretical Biology (1981) 379-80.	1
	CO	BRENT & FINLEY "Understanding gene and allele function with two-hybrid methods," 31	
		Annual Review of Genetics (1997) 663-704.	L
	CP	LEGRAIN & SELIG "Genome-wide protein interaction maps using two-hybrid systems,"	
		480 FEBS Letters (2000) 32-36.	Ļ
	CQ	VIDAL & LEGRAIN "Yeast forward and reverse 'n'-hybrid systems," 27 Nucleic Acids	
		Research (1999) 919-29.	L
	CR	EDWARDS & LEATHERBARROW "Determination of Association rate constants by an optical	
		biosensor using initial rate analysis," 246 Analytical Biochemistry (1997) 1-6.	Ļ
	CS	GOLDSPIEL et al. "Clinical Frontiers; Human gene therapy," 12 Clin. Pharm. (1993) 488-505.	L
	СТ	FIELDS & SONG "A novel genetic system to detect protein-protein interactions," 340 Nature (1989)245-6.	
	CU	REYNOLDS et al., "Chimeric viral vectors the best of both worlds?" Molecular Medicine	
		Today (1999) 25-31.	↓
	CV	VIDAL et al. "Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-	
		protein and DNA-protein interactions" 93 Proc. Natl. Acad. Sci USA (1996) 10315-20.	1
	CW	TIRODE et al. "A conditionally expressed third partner stabilizes or prevents the formation of a	
		transcriptional activator in a three-hybrid system," 272 J. Biol. Chemistry (1997) 22995-99.	ļ.
	CX	JEFFREY S. FLIER, "The adipocyte: storage depot or node on the energy information	
		superhighway?" 80 Cell (1995) 15-18.	_
	CY	ZHANG et al. "Positional cloning of the mouse obese gene and its human homologue,"	
		372 Nature (1994) 425-32.	ļ
	CZ	PELLEYMOUNTER et al, "Effects of the obese gene product on body weight regulation in	
	}	ob/ob mice," 269 Science (1995) 540-43.	1
	CA1	SALTIEL et al. "Thiazolidinediones in the treatment of insulin resistance and type II diabetes,"	
	1	45 Diabetes (1996) 1661-69.	1
	CB1	SREENAN et al., "Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment	1
		with metformin or troglitazone," 271 Am. J. Physiology (1996) E742-7.	1
	CC1	NOLAN et al. "Improvement in glucose tolerance and insulin resistance in obese subjects	
		treated with troglitazone," 331 New England J. Med. (1994) 1188-93.	1
	CD1	TONTONOZ et al. "Stimulation of adipogenesis in fibroblasts by PPARy2, a lipid-activated	
	L	transcription factor," 79 Cell (1994) 1147-56.	1
	CE1	LEHMANN et al. "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome	1
	1	proliferator-activated receptor y (PPARy)," 270 J. Biol. Chem. (1995) 12953-55.	

Examiner Date Considered		
Longidored	Examiner	Date
I Signature     Considered		Considered
	Signature	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.